AICPA Wants More Guidance on R&D Expensing

Why It Matters

Clarifying the Section 174A(c) election will give taxpayers predictable, administrable R&D tax treatment, influencing corporate innovation budgeting and compliance costs.

Key Takeaways

• AICPA seeks clarification on Section 174A(c) election.
• OBBBA restores immediate deduction for domestic R&D after 2024.
• Conflicting language in Rev. Proc. 2025‑28 creates interpretation variance.
• AICPA proposes project‑by‑project or yearly election options.
• Simplified mid‑year safe harbor method suggested for benefit timing.

Pulse Analysis

The recent One Big Beautiful Bill Act marks a pivotal shift in U.S. tax policy, undoing the five‑year amortization mandate imposed by the 2017 Tax Cuts and Jobs Act. By reinstating the ability to expense domestic research and development costs in the year incurred, the OBBBA aims to accelerate cash flow for innovators and align federal treatment with many state regimes that already permitted immediate deductions. However, the transition has been muddied by ambiguous language in Revenue Procedure 2025‑28, leaving tax practitioners uncertain whether the Section 174A(c) election operates as a method of accounting or a taxable‑year election.

The AICPA’s request for guidance addresses this uncertainty head‑on. It recommends that the IRS clarify the election’s scope, allowing taxpayers to apply it either on a project‑by‑project basis or uniformly across a taxable year. Such flexibility would accommodate diverse R&D portfolios—ranging from single‑project startups to multinational corporations with concurrent domestic and foreign research—while preserving administrative simplicity. Additionally, the institute’s proposal for a safe‑harbor rule that treats the midpoint of the fiscal year as the benefit realization month would eliminate the need for granular, case‑by‑case analyses that currently consume significant tax‑compliance resources.

If the Treasury adopts these recommendations, the immediate deduction of R&D expenses could become a more reliable tool for corporate financial planning, encouraging higher investment in innovation. Clear, consistent guidance would also reduce audit risk and litigation, fostering a more stable tax environment for the technology and biotech sectors that rely heavily on research incentives. Ultimately, the move could strengthen the United States’ competitive edge by ensuring that tax policy supports, rather than hinders, rapid development cycles in high‑growth industries.